scholarly journals Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients

2016 ◽  
Vol 21 (3) ◽  
pp. 292-300 ◽  
Author(s):  
Fortunato Ciardiello ◽  
Richard Adams ◽  
Josep Tabernero ◽  
Thomas Seufferlein ◽  
Julien Taieb ◽  
...  
Oncotarget ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 1-14
Author(s):  
Elena Fountzilas ◽  
Vassiliki Kotoula ◽  
Georgia-Angeliki Koliou ◽  
Eleni Giannoulatou ◽  
Helen Gogas ◽  
...  

2021 ◽  
Author(s):  
Stefano Olgiati ◽  
Nima Heidari ◽  
Davide Meloni ◽  
Federico Pirovano ◽  
Ali Noorani ◽  
...  

Background Quantum computing (QC) and quantum machine learning (QML) are promising experimental technologies which can improve precision medicine applications by reducing the computational complexity of algorithms driven by big, unstructured, real-world data. The clinical problem of knee osteoarthritis is that, although some novel therapies are safe and effective, the response is variable, and defining the characteristics of an individual who will respond remains a challenge. In this paper we tested a quantum neural network (QNN) application to support precision data-driven clinical decisions to select personalized treatments for advanced knee osteoarthritis. Methods Following patients consent and Research Ethics Committee approval, we collected clinico-demographic data before and after the treatment from 170 patients eligible for knee arthroplasty (Kellgren-Lawrence grade ≥ 3, OKS ≤ 27, Age ≥ 64 and idiopathic aetiology of arthritis) treated over a 2 year period with a single injection of microfragmented fat. Gender classes were balanced (76 M, 94 F) to mitigate gender bias. A patient with an improvement ≥ 7 OKS has been considered a Responder. We trained our QNN Classifier on a randomly selected training subset of 113 patients to classify responders from non-responders (73 R, 40 NR) in pain and function at 1 year. Outliers were hidden from the training dataset but not from the validation set. Results We tested our QNN Classifier on a randomly selected test subset of 57 patients (34 R, 23 NR) including outliers. The No Information Rate was equal to 0.59. Our application correctly classified 28 Responders out of 34 and 6 non-Responders out of 23 (Sensitivity = 0.82, Specificity = 0.26, F1 Statistic= 0.71). The Positive (LR+) and Negative (LR-) Likelihood Ratios were respectively 1.11 and 0.68. The Diagnostic Odds Ratio (DOR) was equal to 2. Conclusions Preliminary results on a small validation dataset show that quantum machine learning applied to data-driven clinical decisions for the personalized treatment of advanced knee osteoarthritis is a promising technology to reduce computational complexity and improve prognostic performance. Our results need further research validation with larger, real-world unstructured datasets, and clinical validation with an AI Clinical Trial to test model efficacy, safety, clinical significance and relevance at a public health level.


2020 ◽  
Vol 15 (3) ◽  
pp. 187-194
Author(s):  
Amelia Licari ◽  
Riccardo Castagnoli ◽  
Enrica Manca ◽  
Martina Votto ◽  
Alexander Michev ◽  
...  

Pediatric severe asthma is actually considered a rare disease with a heterogeneous nature. Recent cohort studies focusing on children with severe asthma identified different clinical presentations (phenotypes) and underlying pathophysiological mechanisms (endotypes). Phenotyping and endotyping asthma represent the current approach to patients with severe asthma and consist in characterizing objectively measurable and non-invasive indicators (biomarkers) capable of orienting diagnosis, management and personalized treatment, as advocated by the Precision Medicine approach. The aim of this review is to provide a practical overview of current and emerging biomarkers in pediatric severe asthma.


Author(s):  
Jay G. Ronquillo ◽  
William T. Lester

PURPOSE The rapid growth of biomedical data ecosystems has catalyzed research for oncology and precision medicine. We leverage federal cloud-based precision medicine databases and tools to better understand the current landscape of precision medicine and genomic testing for patients with cancer. METHODS Retrospective observational study of genomic testing for patients with cancer in the National Institutes of Health All of Us Research Program, with the cancer cohort defined as having at least two documented or reported cancer diagnoses. RESULTS There were 5,678 (1.8%) All of Us participants in the cancer cohort, with a significant difference between cancer status by age category, sex, race, and ethnicity ( P < .001 for all). There were 295 (5.2%) patients with cancer who received genomic testing compared with 6,734 (2.2%) of noncancer patients, with 752 genomic tests commonly focused on gene mutations (primarily pharmacogenomics), molecular pathology, or clinical cytogenetic reports. CONCLUSION Although not yet ubiquitous, diverse clinical genomic analyses in oncology can set the stage to grow the practice of precision medicine by integrating research patient data repositories, cancer data ecosystems, and biomedical informatics.


Author(s):  
Elisabeth Salzer ◽  
Caroline Hutter

SummaryCancer remains the leading cause of death from disease among children beyond the age of one. Survival of pediatric patients with cancer has dramatically improved over the last decades but some tumors remain almost intractable and relapse is still associated with an infaust prognosis. Despite the heterogeneity of pediatric malignancies, most treatments include the same set of generic therapies.  Optimizing delivery of conventional therapeutics has been the driving force behind continuous improvements but further escalation of conventional therapy is unlikely to improve outcomes. The limited success of targeted drugs in pediatric cancer patients, originally developed for cancers in adults, can be connected to the different etiology of tumors in children versus adults. In addition, many pediatric cancers lack reliable biomarkers, cannot be studied in large cohorts and only few available therapies target abberations specific for certain pediatric cancers.These observations have led to the establishment of pediatric precision-medicine programs. The major goal of these programs is to identify patient-tailored molecular treatment plans that will eventually improve quality of life and survival. Despite the initial euphemism, the impact of actionable matched treatments and the most adequate value-based genomics strategies are not yet well established. A non-competitive collaborative model based on pediatric cancer priorities and strong collaboration between academia, pharmaceutical companies and regulators is needed. In the near future, clinical trials need to focus on biologically defined patient subsets, in an even smaller patient population. A major collaborative effort between all associated groups will be necessary to ensure success of pediatric precision cancer medicine.


Sign in / Sign up

Export Citation Format

Share Document